| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 80.0 | ¤9,361 | CN |
| 000999.CN | China Resources Sanjiu Medical & Pharmac | 58.9 | ¤7,616 | CN |
| 300832.CN | Shenzhen New Industries Biomedical Engin | 61.1 | ¤6,547 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 83.6 | ¤6,125 | CN |
| 688336.CN | Sunshine Guojian Pharmaceutical (Shangha | 55.6 | ¤4,969 | CN |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 301580.CN | Aidite (Qinhuangdao) Technology Co., Ltd | 57.9 | ¤577 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 59.6 | ¤585 | CN |
| 688253.CN | Innovita Biological Technology Co., Ltd. | 50.3 | ¤610 | CN |
| 603439.CN | GuiZhou SanLi Pharmaceutical Co., Ltd. C | 46.3 | ¤674 | CN |
| 688581.CN | Hangzhou AGS MedTech Co. Ltd. | 62.1 | ¤717 | CN |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| 000999.CN | China Resources Sanjiu Medical & Pharmac | 58.9 | 18 | CN |
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 80.0 | 18 | CN |
| 000423.CN | Dong-E-E-Jiao Co., Ltd. Class A | 68.4 | 17 | CN |
| 600566.CN | HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Cl | 50.4 | 16 | CN |
| 300529.CN | Jafron Biomedical Co., Ltd. Class A | 51.6 | 8 | CN |
| 600216.CN | Zhejiang Medicine Co., Ltd. Class A | 61.1 | 8 | CN |
| 600285.CN | Henan Lingrui Pharmaceutial Co., Ltd. Cl | 75.8 | 7 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 59.6 | 6 | CN |
| 600779.CN | Sichuan Swellfun Co., Ltd. Class A | 62.0 | 6 | CN |
| 300705.CN | Hunan Jiudian Pharmaceutical Co. Ltd. Cl | 70.1 | 5 | CN |
| Average Market Cap | ¤2,732 |
| Median Market Cap | ¤1,846 |
| Avg. 3 Mo. Dollar Vol. | ¤29,847,154 |
| Avg. 3 Mo. Trading Vol. | 7,931,157 |
| Last Rebalance Date | 12/16/2024 |
| Companies Replaced | 11 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 21.2 |
| Forward P/E Ratio (12 Mo.) | 14.1 |
| Price/Book Ratio | 3.3 |
| Avg. Revenue Chg. - 3 Yr | 54.7% |
| Avg. Op. Income Chg. - 3 Yr. | 65.1% |
| Avg. EPS Growth - 3 Yr. | 22.5% |
| Avg. EPS Growth - 1 Yr. | 27.5% |
| Avg. Operating Margin | 24.1% |
| Avg. LT Debt to Total Capital | 7.7% |
| Avg. Return on Equity | 16.2% |
| Dividend Yield | 1.7% |
| China Health Care Index | 59.64 |
| China | 100.0% |
